Skip to main content

Table 1 Outcomes over the whole INBUILD trial in subgroups by BMI at baseline

From: Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial

 

BMI < 25 kg/m2

BMI ≥ 25 to < 30 kg/m2

BMI ≥ 30 kg/m2

Nintedanib

(n = 90)

Placebo

(n = 98)

Nintedanib

(n = 130)

Placebo

(n = 112)

Nintedanib

(n = 111)

Placebo

(n = 121)

Acute exacerbation or death, n (%) with event

12 (13.3)

24 (24.5)

18 (13.8)

24 (21.4)

16 (14.4)

17 (14.0)

 Hazard ratio (95% CI)

0.52 (0.26, 1.04)

0.66 (0.36, 1.21)

0.92 (0.47, 1.83)

 Treatment-by-subgroup interaction

p = 0.52

Progression of ILDa or death, n (%) with event

44 (48.9)

59 (60.2)

48 (36.9)

61 (54.5)

42 (37.8)

61 (50.4)

 Hazard ratio (95% CI)

0.74 (0.50, 1.10)

0.65 (0.44, 0.94)

0.64 (0.43, 0.95)

 Treatment-by-subgroup interaction

p = 0.85

  1. Analyzed as time to first event
  2. BMI body mass index, ILD interstitial lung disease
  3. aAbsolute decline in forced vital capacity % predicted ≥ 10%